Premium
Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide
Author(s) -
Wolthers Ole D.,
Riis Bente Juel,
Pedersen Søsren
Publication year - 1993
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950160604
Subject(s) - medicine , budesonide , prednisolone , bone remodeling , endocrinology , osteocalcin , creatinine , asthma , hydroxyproline , adverse effect , excretion , alkaline phosphatase , chemistry , biochemistry , enzyme
Biochemical markers of bone turnover were studied in prepubertal school children with asthma in two randomized double‐blind crossover trials with run‐in, treatment, and wash‐out periods of 2 weeks. One group (n = 11) was treated with 2.5 and 5.0 mg prednisolone, the other (n = 14) with 200 and 800 μg inhaled budesonide per day. Serum osteocalcin, serum total alkaline phosphatase, fasting urinary excretion of hydroxyproline and calcium, serum 25‐hydroxyvitamin D, and 1,25 dihydroxyvitamin D were assessed. A dose‐related reduction of serum osteocalcin (Page's test for trend: P = 0.04; z = −2.3) and of the fasting urinary hydroxypro1ine:creatinine ratio (Page's test for trend: P = 0.05; z = −2.0) was found in the children who were treated with prednisolone. Inhaled budesonide was not associated with statistically significant effects on any of the biochemical markers. Short‐term treatment with low daily doses of prednisolone may cause a suppression of bone turnover in children with asthma. To reduce the risk of adverse effects on bone turnover, doses of inhaled budesonide up to 800 μg daily may be preferable to low doses of prednisolone. Bone turnover remains to be evaluated during long‐term treatment. Pediatr Pulmonol. 1993; 16:341–346. © 1993 Wiley‐Liss, Inc.